Many patients with relapsed/refractory (R/R) DLBCL are ineligible for intensive treatment such as stem-cell transplant due to age or comorbidities. Globally, the combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx) is one of the most widely used therapies among transplant ineligible patients with R/R DLBCL. However, little recent real-world evidence exists on this treatment regimen, particularly in older adults.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.